Therapeutic cleavage of IgG: new avenues for treating inflammation

Trends in Immunology

Volumn 29, Issue 4, 2008, Pages 173-178

  Nandakumar, Kutty Selva ^a   Holmdahl, Rikard ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BACTERIAL ENZYME; CARBOHYDRATE; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; N ACETYL BETA GLUCOSAMINIDASE;

ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DRUG ACTIVITY; DRUG ELIMINATION; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOGENICITY; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PLASMAPHERESIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; BACTERIAL PROTEINS; GLYCOSIDE HYDROLASES; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; STREPTOCOCCUS PYOGENES;

EID: 41349090782     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2008.01.007     Document Type: Review

References (55)

1. Colvin R.B., and Smith R.N. Antibody-mediated organ-allograft rejection. Nat. Rev. Immunol. 5 (2005) 807-817
2. Tuscano J.M., et al. B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications. Autoimmun. Rev. 2 (2003) 101-108
3. Martin F., and Chan A.C. B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol. 24 (2006) 467-496
4. Blank M., and Shoenfeld Y. B cell targeted therapy in autoimmunity. J. Autoimmun. 28 (2007) 62-68
5. Edwards J.C., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2572-2581
6. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5 (2006) 564-576
7. Silverman G.J. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Front. Biosci. 12 (2007) 2194-2206
8. Sanz I., et al. B cell depletion therapy in autoimmune diseases. Front. Biosci. 12 (2007) 2546-2567
9. Manz R.A., et al. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23 (2005) 367-386
10. Radbruch A., et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6 (2006) 741-750
11. Fukuyama H., et al. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat. Immunol. 6 (2005) 99-106
12. Xiang Z., et al. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8 (2007) 419-429
13. Ravetch J.V., and Nussenzweig M. Killing some to make way for others. Nat. Immunol. 8 (2007) 337-339
14. Scofield R.H. Autoantibodies as predictors of disease. Lancet 363 (2004) 1544-1546
15. Nandakumar K.S., et al. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum. 58 (2007) 184-196
16. Amirahmadi S.F., et al. An arthritogenic monoclonal antibody to type II collagen, CII-C1, impairs cartilage formation by cultured chondrocytes. Immunol. Cell Biol. 82 (2004) 427-434
17. Gray R.E., et al. Measurement of antibodies to collagen II by inhibition of collagen fibril formation in vitro. J. Immunol. Methods 285 (2004) 55-61
18. Amirahmadi S.F., et al. Arthritogenic anti-type II collagen antibodies are pathogenic for cartilage-derived chondrocytes independent of inflammatory cells. Arthritis Rheum. 52 (2005) 1897-1906
19. Crombie D.E., et al. Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro. Arthritis Res. Ther. 7 (2005) R927-R937
20. Sitaru C., and Zillikens D. Mechanisms of blister induction by autoantibodies. Exp. Dermatol. 14 (2005) 861-875
21. Sitaru C., et al. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch. Dermatol. Res. 299 (2007) 1-8
22. Lacroix-Desmazes S., et al. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J. Immunol. 177 (2006) 1355-1363
23. Stegmayr B.G. A survey of blood purification techniques. Transfus Apher Sci. 32 (2005) 209-220
24. Gorbet M.B., and Sefton M.V. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 25 (2004) 5681-5703
25. Nilsson B., et al. The role of complement in biomaterial-induced inflammation. Mol. Immunol. 44 (2007) 82-94
26. Gaubitz M., and Schneider K.M. Immunoadsorption in systemic lupus erythematosus: different techniques and their current role in medical therapy. Ther. Apher. Dial. 7 (2003) 183-188
27. Collin M., and Olsen A. Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes. Infect. Immun. 71 (2003) 2983-2992
28. von Pawel-Rammingen U., and Bjorck L. IdeS and SpeB: immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes. Curr. Opin. Microbiol. 6 (2003) 50-55
29. Vincents B., et al. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry 43 (2004) 15540-15549
30. Wenig K., et al. Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17371-17376
31. Hess J.L., et al. Immunoglobulin cleavage by the streptococcal cysteine protease IdeS can be detected using protein G capture and mass spectrometry. J. Microbiol. Methods 70 (2007) 284-291
32. Nandakumar K.S., et al. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo. Arthritis Rheum. 56 (2007) 3253-3260
33. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21 (2005) 11-16
34. Walsh G., and Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24 (2006) 1241-1252
35. Arnold J.N., et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25 (2007) 21-50
36. Nezlin R., and Ghetie V. Interactions of immunoglobulins outside the antigen-combining site. Adv. Immunol. 82 (2004) 155-215
37. Nimmerjahn F., and Ravetch J.V. Fc-Receptors as regulators of immunity. Adv. Immunol. 96 (2007) 179-204
38. Krapp S., et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325 (2003) 979-989
39. Jefferis R. A sugar switch for anti-inflammatory antibodies. Nat. Biotechnol. 24 (2006) 1230-1231
40. Kanda Y., et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17 (2007) 104-118
41. Shinkawa T., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
42. Nimmerjahn F., and Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005) 1510-1512
43. Nechansky A., et al. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Mol. Immunol. 44 (2007) 1815-1817
44. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 7 (2007) 1401-1413
45. Kaneko Y., et al. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673
46. Nimmerjahn F., and Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 204 (2007) 11-15
47. Baudino L., et al. Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies. Springer Semin. Immunopathol. 28 (2006) 175-184
48. Scallon B.J., et al. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44 (2007) 1524-1534
49. Nandakumar K.S., et al. Endoglycosidase treatment abrogates IgG arthritogenicity: Importance of IgG glycosylation in arthritis. Eur. J. Immunol. 37 (2007) 2973-2982
50. Cai J., and Terasaki P.I. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum. Immunol. 66 (2005) 334-342
51. Terasaki P., and Mizutani K. Antibody mediated rejection: update 2006. Clin. J. Am. Soc. Nephrol. 1 (2006) 400-403
52. Sheridan C. TeGenero fiasco prompts regulatory rethink. Nat. Biotechnol. 24 (2006) 475-476
53. Aslam A., et al. Proteases from Schistosoma mansoni cercariae cleave IgE at solvent exposed interdomain regions. Mol. Immunol. 45 (2008) 567-574
54. Akesson P., et al. IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection. Infect. Immun. 74 (2006) 497-503
55. Gearing A.J., et al. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol. Lett. 81 (2002) 41-48